Arabic Arabic English English French French German German
dark

Verastem Oncology Outlines Key 2022 Strategic Priorities and Upcoming Catalysts for Advancing VS-6766 as a Backbone of Therapy for RAS Pathway-Driven Cancers

Verastem Oncology today outlined key strategic priorities and upcoming catalysts to support its lead compound VS-6766 in 2022. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Ketamine and psychological therapy helped severe alcoholics abstain for longer in trial

Next Post

New Peripheral Vascular Microcatheters Save Procedure Time and Advance Treatment Capabilities

Related Posts
Total
0
Share